Document is current
Any future updates will be listed below
-
Authors
Deak, Joseph D. https://orcid.org/0000-0002-0540-6080
Zhou, Hang https://orcid.org/0000-0002-7694-6391
Galimberti, Marco https://orcid.org/0000-0001-6052-156X
Levey, Daniel F. https://orcid.org/0000-0001-8431-9569
Wendt, Frank R. https://orcid.org/0000-0002-2108-6822
Sanchez-Roige, Sandra
Hatoum, Alexander S.
Johnson, Emma C. https://orcid.org/0000-0003-0394-777X
Nunez, Yaira Z.
Demontis, Ditte https://orcid.org/0000-0001-9124-2766
Børglum, Anders D. https://orcid.org/0000-0001-8627-7219
Rajagopal, Veera M. https://orcid.org/0000-0002-5236-168X
Jennings, Mariela V.
Kember, Rachel L. https://orcid.org/0000-0001-8820-2659
Justice, Amy C.
Edenberg, Howard J. https://orcid.org/0000-0003-0344-9690
Agrawal, Arpana https://orcid.org/0000-0002-0313-793X
Polimanti, Renato https://orcid.org/0000-0003-0745-6046
Kranzler, Henry R. https://orcid.org/0000-0002-1018-0450
Gelernter, Joel https://orcid.org/0000-0002-4067-1859
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA054869, DP1 DA054394, R01DA054869, R01DA054869, K02 DA032573, R33 DA047527)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01 AA026364, T32 AA028259, K01 AA028292, U24 AA020794, U01 AA020790, U10 AA013566)
U.S. Department of Veterans Affairs (I01CX001849, I01BX003342, I01BX003342, I01BX003342, I01BX004820)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
Brain Research Foundation
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (F32 MH122058)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Lundbeckfonden (R102-A9118, R155-2014-1724, R248-2017-2003, R155-2014-1724, R248-2017-2003)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
- License Information
-
More Information
Article History
Received: 12 May 2022
Accepted: 8 July 2022
First Online: 25 July 2022
Competing interests
: HRK is a member of scientific advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sophrosyne Pharmaceuticals; and a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which during the past three years was supported by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018 and issued on January 26, 2021 as U.S. Patent No. 10,900,082. JG and RP were paid for editorial work for the journal “Complex Psychiatry.” All other authors report no biomedical financial interests or potential conflicts of interest.
